You are here:

pregabalin (Lyrica)

Advice

Following a second resubmission

pregabalin (Lyrica) is accepted for restricted use within NHS Scotland for the treatment of peripheral neuropathic pain in adults. The clinical evidence of efficacy in patients with peripheral neuropathic pain who are refractory to treatment was based on open-label, uncontrolled, non-randomised studies, with small patient numbers and different methodologies.

Pregabalin is restricted to use in patients who have not achieved adequate pain relief from, or have not tolerated, conventional first and second line treatments for peripheral neuropathic pain. Treatment should be stopped if the patient has not shown sufficient benefit within 8 weeks of reaching the maximally tolerated therapeutic dose.

Drug Details

Drug Name: pregabalin (Lyrica)
SMC Drug ID: 157/05
Manufacturer: Pfizer Ltd
Indication: Peripheral neuropathic pain
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Resubmission
Status: Restricted
Date Advice Published: 11 May 2009

Archived Advice

IRP 7 August 2006
Resubmission 15 August 2005
Full submission 7 March 2005

Back